ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 327

AMPK Activation in Inflammatory Arthritis

Monica Guma1, Yun Wang2 and Ru Liu-Bryan2, 1Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 2UCSD/VAMC, La Jolla, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, Fibroblasts, Macrophage, metabolism and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase involved in the regulation of cellular energy homeostasis. It is a central regulator of both lipid and glucose metabolism. Many studies have suggested that AMPK activation can also exert significant anti-inflammatory and immunosuppressive effects. We evaluated whether modulating this pathway altered pathogenic mechanisms in inflammatory arthritis.

Methods: The AMPK agonist A-769662 (60mg/kg/bid) was tested in two arthritis models: In antigen induced arthritis (AIA), mice were primed with mBSA in complete Freund’s adjuvant and then given an intraarticular challenge with mBSA in the knee on day 21. In passive serum arthritis, K/BxN serum was injected on day 0. Joints were harvested and prepared for histological assessment. IL-6 expression in joints and sera was measured by ELISA. Human fibroblast-like synoviocyte (FLS) and bone marrow derived macrophage (BMDM) function was tested using A-769662 (250uM) as follows: 1) phosphorylation of p65 NF-kappaB by Western Blot, 2) IL-6 secretion by ELISA, 3) NO secretion by Griess method, 4) cell survival in H2O2 treated cells by phase contrast light microscopy.

Results: AMPK pathway activation by A-769662 reduced inflammatory infiltration and joint damage in both animal models. In passive K/BxN model, day 8 scores were 8.2±3 and 2.4±3 (P<0.05) for vehicle and A-769662-treated mice, respectively. In AIA model joint histology scores for vehicle and A-769662-treated mice for synovial hypertrophy were 2.9±0.9 and 1.6±1.1 (p=0.01), bone erosion scores were 2.2±1 and 1.5±1.1 (p<0.05), and cartilage damage scores were 2±0.6 and 1.2±0.6 (p<0.05), respectively. IL-6 expression in serum and arthritic joints was significantly decreased in A-769662 treated mice. The mechanism of AMPK action was evaluated in FLS and BMDM. AMPK activation with A-762664 reduced IL-6 and NO secretion by 52±5.6% and 76±7.5 %respectively (p<0.05), and p65 NF-kappaB phosphorylation after TLR stimulation in BMDM. Additionally, AMPK activation also significantly increased H2O2-induced apoptosis in FLS.

Conclusion:   Activating AMPK pathway suppressed inflammatory arthritis in mice as well as IL-6 expression in serum, arthritic joints and cultured BMDM. These data suggest that AMPK signaling activation could be an effective therapeutic strategy for IL-6 dependent inflammatory arthritis.


Disclosure:

M. Guma,
None;

Y. Wang,
None;

R. Liu-Bryan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ampk-activation-in-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology